Best Immunotherapy for kidney cancer Doctors Worldwide — TOP 52

Dr. Bulent Karagoz is a medical oncologist at Anadolu Medical Center in Istanbul. He specializes in immunotherapy and targeted therapies for sarcoma, lymphoma, and lung cancer. Dr. Karagoz provides treatment at a facility affiliated with the prestigious Johns Hopkins Hospital.

• Authored over 40 research publications focusing on tumor biology and immunology.
• Former Head of Internal Diseases at Istanbul Okan University Faculty of Medicine.
• Held leadership roles in medical oncology at GATA Haydarpasa Training Hospital.
• Member of the Turkish Medical Oncology Association and European Head and Neck Society.

Senior oncologist at Sourasky Medical Center with expertise in kidney cancer immunotherapy. Educated in the UK, Israel, and Georgia, bringing an international perspective to treatment.

• Principle investigator of clinical trials in cancer therapies
• Published 30+ articles on cancer treatment
• Specialized training in cancer urology from Oxford University
• Member of leading oncology societies including ESMO and ASCO

Prof. Merimsky leads the Soft Tissue and Bone Oncology unit at Sourasky Medical Center – Israel's top facility for rare cancers.

• 41 years of experience specializing in sarcoma and kidney cancer
• ESMO faculty member for sarcoma treatments
• Fellowship-trained at Institut Gustave Roussy in Paris
• Published research on immunotherapy monitoring

Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.

Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.

Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.

Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.

He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.

Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.

He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).

Professor Sağlam specializes in medical oncology at Gayrettepe Florence Nightingale Hospital, focusing on advanced treatments for kidney cancer.

• Over 27 years of experience of experience in medical oncology
• Trained at Istanbul University – one of Turkey's leading medical institutions
• Member of ESMO, ASCO, and European Neuroendocrine Tumour Society
• Published research in gastrointestinal oncology

Dr. Osama Abdel Mohimen Mohamed leads the Hematology Unit at Shefaa Al Orman Oncology Hospital. He treats complex blood cancers, including leukemia, lymphoma, and myeloma. Dr. Mohamed is a member of the European Society for Medical Oncology. He also holds memberships in the American Society of Hematology and ASBMT.

• Specializes in chemotherapy, immunotherapy, and bone marrow transplantation.
• Manages aggressive acute leukemia and chronic blood disorders.
• Treats complications arising from various solid tumors.
• Works at an ESMO-accredited center that handles 6,000 patients annually.

Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).

He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.

Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.

Dr. Sinan Karaaslan is a medical oncologist at Anadolu Medical Center in Istanbul. He specializes in treating breast, colorectal, and urogenital system cancers. Dr. Karaaslan brings clinical expertise from major institutions, including Medical Park and Gülhane Military Medical Academy. He works at a hospital affiliated with the Johns Hopkins Hospital.

• Holds personal certification from the European Society for Medical Oncology.
• Treats complex conditions, including stage 4 colon and lung cancers.
• Member of the Turkish Medical Oncology and Turkish Lung Cancer societies.
• Performs systemic therapies such as immunotherapy, targeted therapy, and chemotherapy.

Dr. Solak specializes in immunotherapy for kidney cancer at Hisar Hospital Intercontinental, with a strong background in oncology.

• Fellowship trained at Hacettepe University Cancer Institute
• Worked at The University of Texas MD Anderson Cancer Center
• Experienced in treating various cancers including lung and gastrointestinal cancers
• Board-certified in oncology with extensive clinical practice

Professor Yesim Yildirim specializes in cancer immunotherapy and targeted therapies, with over 80 publications in oncology.

• Member of European Society of Medical Oncology (ESMO)
• Trained in Melanoma and Kidney Cancer Clinic at Mount Vernon Cancer Center
• Professor at Halic University with extensive academic credentials
• Works at Anadolu Medical Center since 2011

Assoc. Prof. Dr. Heves Sürmeli is a specialist in Internal Medicine and Medical Oncology. She received her medical degree (M.D.) from Eskişehir Osmangazi University in 2004. She completed her Internal Medicine residency at Kartal Dr. Lütfi Kırdar Training and Research Hospital, Istanbul (2005–2010). She then completed subspecialty training in Medical Oncology at the same hospital (2014–2017).

At the same center, she served as a Medical Oncology Specialist (2017–2023). She then worked as Administrative and Clinical Director (2023–2026). Her clinical interests include breast, lung, gynecologic, gastrointestinal, and urologic cancers.

She has published many articles in international peer‑reviewed journals. She has presented at national and international conferences. She is active in professional societies. She has received several awards.

Dr. Seref Komurcu is a medical oncologist at Anadolu Medical Center in Istanbul. He specializes in treating breast, lung, colorectal, and solid cancers. Dr. Komurcu holds both ECFMG and ESMO certifications. He previously served as a professor at Gülhane Military Medical Academy.

• Published over 110 scientific papers on cancer management.
• Provides immunotherapy, targeted therapy, and chemotherapy treatments.
• Member of the American Society of Clinical Oncology.
• Works at a clinic affiliated with Johns Hopkins Medicine.

Dr. Eda Tanrikulu is a clinical oncologist at Anadolu Medical Center in Istanbul. She ranked 3rd nationally in Turkey's minor specialty medical exam. Dr. Tanrikulu specializes in chemotherapy and individualized cancer treatments. She works at a facility affiliated with the Johns Hopkins Hospital.

• Served as the head of the medical oncology unit at Haydarpaşa Numune Hospital.
• Participated in global training at Oxford University and ESMO in Manchester.
• Treats gastrointestinal, urological, lung, and breast cancers.
• Member of the American and European Societies of Medical Oncology.

Dr. Necdet Uskent is a medical oncologist and hematologist at Anadolu Medical Center in Istanbul. He was part of the pioneering team that performed Turkey's first bone marrow transplant. Dr. Uskent holds the European Medical Oncology Certificate and focuses on breast, lung, and gastrointestinal cancers. He works at a facility affiliated with Johns Hopkins Medicine.

• Founder of the Turkish Oncology Group (TOG).
• A founding member of the Turkish Society of Medical Oncology.
• Served as a visiting lecturer at Royal Free and University College Hospital in London.
• Treats complex hematological conditions including lymphomas and myeloma.

Director of oncology hospitalization at Tel Aviv Medical Center – Dr. Stepfansky leads immunotherapy programs for kidney cancer.

• 26 years of experience specializing in oncology
• Primary researcher in multiple clinical trials for kidney cancer treatments
• Trained at Tel Aviv Medical Center's prestigious oncology department
• Board-certified in both internal medicine and oncology

Dr. Dror Levin specializes in pediatric hematology and oncology, with a focus on bone cancer (sarcoma) in children at Sourasky Medical Center.

• Director of children's hematology oncology department at Sourasky Medical Center
• Specialized in pediatric hematology and oncology at Schneider Children's Medical Center
• Member of the Israeli association for pediatric hemato-oncology (ISPHO)
• Studied bone and soft tissue oncology at Rizzoli Orthopaedic Institute in Italy

Professor of Medical Oncology with over 29 years of experience of experience – Dr. Saglam specializes in immunotherapy for kidney cancer at Istanbul Florence Nightingale Hospital.

• Fellowship-trained at Istanbul University Oncology Institute
• Member of ESMO, ASCO, and Turkish Medical Oncology Association
• Attending physician in Gastrointestinal Oncology
• Extensive experience in clinical oncology research

Specializes in advanced immunotherapy for kidney cancer with molecular diagnostics expertise. Leads the certified cancer center in Solingen.

• 14 years of experience in oncology with dual specialization in hematology and immunology
• Qualified in genetics for precision treatment approaches
• Active researcher in molecular biology for innovative cancer therapies
• Member of American Association for Cancer Research and German oncology societies